Evidence map›Paper›PMID 32269232›Full record

ArticleScientific reports2020

Polyfunctional HIV-1 specific response by CD8+ T lymphocytes expressing high levels of CD300a.

Joana Vitallé, Iñigo Terrén, Leire Gamboa-Urquijo, Ane Orrantia, Laura Tarancón-Díez, Miguel Genebat, Manuel Leal, Ezequiel Ruiz-Mateos, Francisco Borrego, Olatz Zenarruzabeitia

Abstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. CD8Heliyon · 2024
    Article
  5. Human IgMInternational journal of molecular sciences · 2023
    Article
  6. Vaccine-Induced CD8Frontiers in immunology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Joana VitalléBiocruces Bizkaia Health Research Institute, Immunopathology Group, 48903, Barakaldo, Spain.
Iñigo TerrénBiocruces Bizkaia Health Research Institute, Immunopathology Group, 48903, Barakaldo, Spain.
Leire Gamboa-UrquijoBiocruces Bizkaia Health Research Institute, Immunopathology Group, 48903, Barakaldo, Spain.
Ane OrrantiaBiocruces Bizkaia Health Research Institute, Immunopathology Group, 48903, Barakaldo, Spain.
Laura Tarancón-DíezClinic Unit of Infectious Diseases, Microbiology and Preventive Medicine, Institute of Biomedicine of Seville (IBiS), Virgen del Rocío University Hospital, University of Seville, CSIC, 41013, Seville, Spain.
Miguel GenebatClinic Unit of Infectious Diseases, Microbiology and Preventive Medicine, Institute of Biomedicine of Seville (IBiS), Virgen del Rocío University Hospital, University of Seville, CSIC, 41013, Seville, Spain.
Manuel LealClinic Unit of Infectious Diseases, Microbiology and Preventive Medicine, Institute of Biomedicine of Seville (IBiS), Virgen del Rocío University Hospital, University of Seville, CSIC, 41013, Seville, Spain.
Ezequiel Ruiz-MateosClinic Unit of Infectious Diseases, Microbiology and Preventive Medicine, Institute of Biomedicine of Seville (IBiS), Virgen del Rocío University Hospital, University of Seville, CSIC, 41013, Seville, Spain.
Francisco BorregoBiocruces Bizkaia Health Research Institute, Immunopathology Group, 48903, Barakaldo, Spain.
Olatz ZenarruzabeitiaBiocruces Bizkaia Health Research Institute, Immunopathology Group, 48903, Barakaldo, Spain. olatz.zenarruzabeitiabelaustegui@osakidetza.eus.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CD300a receptor is found on different CD8+ T cell subsets and its expression has been associated to a more cytotoxic molecular signature. CD300a has an important role in some viral infections and its expression levels are known to be modulated by human immunodeficiency virus (HIV)-1 infection on several cell types. The main objective of this work was to investigate CD300a expression and its regulation during HIV-1 specific CD8+ T cell responses. CD300a receptor expression was analysed by multiparametric flow cytometry on CD8+ T lymphocytes from HIV negative donors, naive HIV-1+ individuals and HIV-1+ subjects under suppressive combined antiretroviral therapy (cART). HIV-1 specific CD8+ T cell response was studied by stimulating cells with HIV-1 derived peptides or with a Gag HIV-1 peptide. Our results showed that HIV-1 specific CD8+ T cells expressing higher levels of CD300a were more polyfunctional showing an increased degranulation and cytokine production. Moreover, we observed an up-regulation of CD300a expression after Gag HIV-1 peptide stimulation. Finally, our results demonstrated an inverse correlation between CD300a expression on CD8+ T lymphocytes and HIV disease progression markers. In conclusion, CD300a expression is associated to a better and more polyfunctional HIV-1 specific CD8+ T cell response.

Indexed as

Antigens, CDAnti-HIV AgentsCD8-Positive T-LymphocytesCells, CulturedCytokinesHIV-1HIV InfectionsHumansReceptors, ImmunologicAntigens, CDAnti-HIV AgentsCD300A protein, humanCytokinesReceptors, Immunologic

Identifiers

PMID32269232
PMCPMC7142067

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.